Business Context and Reporting Period
FibroBiologics, Inc. (FBLG) is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases including wound healing, multiple sclerosis (MS), degenerative disc disease, and psoriasis. The company operates as a single reportable segment and is headquartered in Houston, Texas. This summary covers the fiscal year ended December 31, 2025.
The company has no approved products and has not generated any revenue from product sales. Its primary activities involve research and development (R&D), clinical trial preparation, and capital raising.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(18.6) million | $(11.2) million |
| Operating Expenses | $16.6 million | $13.7 million |
| Cash and Cash Equivalents (Year End) | $4.9 million | $14.0 million |
| Accumulated Deficit | $(54.2) million | $(35.5) million |
| Net Cash Used in Operating Activities | $(16.4) million | $(11.9) million |
| Net Cash Provided by Financing Activities | $7.6 million | $16.9 million |
Note: The filing text does not provide specific gross margin or operating margin data as the company has no revenue.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $7.5 million (67%) year-over-year, driven primarily by higher R&D expenses and non-cash fair value adjustments on debt.
- R&D Expense Growth: R&D expenses rose from $4.5 million in 2024 to $7.4 million in 2025. This 64% increase was attributed to increased drug product and CRO costs ($2.2 million) to prepare for the 2026 clinical trial, along with higher personnel and facility costs.
- Debt Fair Value Loss: The company recorded a $1.8 million loss on the change in fair value of convertible debt in 2025, compared to a $0.2 million gain in 2024. This was due to the payoff of convertible notes and valuation changes.
- Cash Burn: Cash and cash equivalents decreased by $9.1 million during 2025, leaving the company with approximately $4.9 million as of year-end.
- Financing Activity: In 2025, the company raised approximately $6.7 million through three registered direct offerings and received net proceeds from convertible notes, partially offset by repayments of those notes.
Guidance, Outlook, and Risks
Outlook and Pipeline Progress
- CYWC628 (Wound Healing): IND-enabling pre-clinical studies are complete. The company plans to initiate a 12-week Phase 1/2 clinical trial in Australia for diabetic foot ulcers in Q1 2026.
- CYMS101 (Multiple Sclerosis): A Phase 1 study in Mexico was completed with no adverse events. The company plans to file an IND application for a Phase 1/2 trial in the U.S. in H1 2026.
- CYPS317 (Psoriasis): An IND application was filed with the FDA on December 30, 2025, seeking clearance for Phase 1/2 trials.
- CybroCell (Degenerative Disc Disease): IND clearance was received in 2018; the company is working to amend the IND to use fibroblast-derived chondrocyte spheroids.
Material Risks and Contingencies
- Going Concern: Management and the independent auditor have raised substantial doubt about the company's ability to continue as a going concern for the twelve months following the issuance of the report. The company requires substantial additional capital to fund operations and clinical trials.
- Nasdaq Listing Compliance: The company received notifications of non-compliance with Nasdaq Capital Market rules regarding minimum bid price and market value of listed securities (MVLS). While a hearing panel granted a temporary extension to regain compliance by April 13, 2026, failure to meet these standards could result in delisting.
- Internal Controls: A material weakness in internal control over financial reporting was identified due to a lack of segregation of duties, particularly prior to the CFO's arrival in June 2025.
- Manufacturing Delays: The company experienced delays in its planned Australian clinical trial due to manufacturing process issues and sterility concerns with its Contract Development and Manufacturing Organization (CDMO).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.9 million cash balance against the projected burn rate and the timeline for the Q1 2026 clinical trial initiation.
- Capital Raising Plans: Confirm the status of any new financing efforts, given the "substantial doubt" going concern warning and the need for additional funding.
- Nasdaq Compliance Status: Monitor the company's progress in meeting the Nasdaq bid price ($1.00) and MVLS ($35 million) requirements by the April 13, 2026 deadline to avoid delisting.
- Clinical Trial Start Date: Verify the actual start date of the CYWC628 Phase 1/2 trial in Australia, noting previous delays caused by manufacturing issues.
- Internal Control Remediation: Review updates on the remediation plan for the material weakness in internal controls over financial reporting.